Company intelligence / Profile preview

Oriel Therapeutics, Inc.

Research Triangle Park, North Carolina, United Statesfind-and-update.company-information.service.gov.uk ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Oriel Therapeutics develops specialty pharmaceutical products focused on improving respiratory care through innovative inhaled drug delivery systems. The company has conducted several early-stage clinical trials comparing its proprietary combination therapies and devices to established market leaders for asthma treatment. Its main product candidates have reached Phase I equivalence studies with a focus on demonstrating bioequivalence to reference products like Advair Diskus.

Therapeutic areas: Pulmonology
Modalities: Inhaled drug delivery systemsCombination therapies (e.g., salmeterol xinafoate/fluticasone propionate)
Industry: Biotech

Beyond the preview

Go deeper on Oriel Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oriel Therapeutics, Inc..

Explore the full profile